Brand Name
Offirmev
Broad Category
Analgesic / Antipyretic / Non-opioid adjunct
Pharm class
Para-aminophenol derivative
MOA
Exact MOA not fully understood
Central Pathways: activates descending serotonergic inhibitory pathways, inhibits COS in brain without binding to active site, and it may inhibit a central COX-3 variant (animal models)
Receptor modulation: at spinal cord, antagonizes neurotransmission by NMDA, substance P, and NO pathways
metabolites modulate transient receptor potential vanilloid 1 (TRPV1) and TRPA1 channels, and stimulate CB1 in rostral ventromedial medula
Indications / clinical uses
Pain mgmt
Opioid-sparing ERAS
Antipyretic
IV dosing Adults > 50kg
1000 mg infused over 15 min q6h
OR
650mg q4h
MAX dose > 50 kg
4 grams in 24 hours
IV dosing < 50 kg adult
15 mg/kg q6h
MAX dose <50 kg
3 grams in 24 hours
Formulation considerations
Contains mannitol
Chronic Alcoholic MAX dose
2 grams
Onset
15 mins
Peak
1 hour
Duration
4-6 hours
PO first pass?
minimal
Common SE
N/V
HA
Insomnia
Precautions / avoidance
Hepatic Impairment / Acute disease
chronic alcoholism
Chronic malnutrition
Severe hypovolemia
Severe renal impairment
Major concern
Hepatotoxicity
- acetylcysteine
- Leading cause of acute fulminant hepatic failure often requiring transplant
Metabolism
Extensive Hepatic
- CYP2E1 (causes toxic metabolite NAPQI)
- glucuronidation (Primary) glutathione mediated
- sulfation
Elimination
Renal
Vd consideration
Moderate
- moderate tissue distribution
- CNS penetration
Clearance Considerations
Reduced clearance in
- hepatic dysfunction
- severe malnutrition
- chronic alcohol